Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. ('Debiopharm'), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor.
Article content
'The exclusive worldwide licensing agreement with Debiopharm allows for the continued development of lunresertib, a novel PKMYT1 inhibitor, that has demonstrated encouraging results across multiple clinical trials in difficult-to-treat solid tumors. This agreement builds upon the success of Repare and Debiopharm's existing collaboration studying the combination of lunresertib and Debio 0123,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'Our recent business development efforts have continued to enable Repare to focus on the advancement of our clinical priorities and sustained value creation. We remain focused on two ongoing Phase 1 clinical trials with readouts expected in the second half of 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor and the POLAR trial evaluating our RP-3467 Polθ ATPase inhibitor.'
Article content
Under the terms of the agreement, Repare will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. Repare and Debiopharm entered into a clinical study and collaboration agreement in January 2024 to explore the synergy between lunresertib and Debio 0123, a potential best-in-class, brain penetrant and highly selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and take over existing and future development activities related to lunresertib.
Article content
'We are excited to enter into this worldwide license agreement with Repare for lunresertib. Based on very promising Phase 1/1b clinical data, we believe the combination of lunresertib and Debio 0123 is highly synergistic and could potentially drive rapid and deep tumor regressions,' said Bertrand Ducrey, CEO of Debiopharm. 'We believe the synthetic lethality approach of lunresertib in combination with Debio 0123 will allow us to bring this innovative precision therapy to patients with difficult to treat cancers.'
Article content
Continued Prioritization of RP-3467 and RP-1664
Article content
Moving forward, Repare will remain focused on the advancement of its two ongoing Phase 1 clinical trials, POLAR and LIONS. The POLAR clinical trial is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, a small molecule inhibitor of polymerase theta (Polθ) that is a synthetic lethality target associated with BRCA mutations and other genomic alterations, alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. Topline safety, tolerability and early efficacy data from the Phase 1 POLAR clinical trial of RP-3467 alone and in combination with olaparib is expected in the third quarter of 2025. The LIONS clinical trial is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664, a first-in-class, highly selective, oral inhibitor of Polo-like kinase 4 (PLK4) that is a synthetic lethality target associated with TRIM37 overexpression. Initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS clinical trial of RP-1664 is expected in the fourth quarter of 2025.
Article content
About Repare Therapeutics Inc.
Article content
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
Article content
Debiopharm's Commitment to Patients
Article content
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally.
Article content
Forward-Looking Statements
Article content
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of lunresertib to Debiopharm, including the potential benefits of the transaction and the achievement and receipt of milestone payments and royalties under the license agreement; the Company's anticipated cash runway; the timing, progress and results of the Company's ongoing Phase 1 LIONS and POLAR clinical trials; and the potential, tolerability, efficacy and clinical progress of the Company's product candidates, including the potential of lunresertib to treat patients with difficult-to-treat solid tumors as a monotherapy or in combination with Debio 0123. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Average Montreal home price surpasses $1 million
Since Alec Raffa started his real estate career four years ago with Royal LePage, he's seen a steep rise in house prices, with many now costing $1 million. Since Alec Raffa started his real estate career four years ago with Royal LePage, he's seen a steep rise in house prices. His recent listing on Nun's Island is just shy of $1,000,000. 'The supply is nowhere near where the demand is at this time,' he said. New figures released from Centris show the lack of supply is having an impact on the market: the average home in price in Montreal is now $1,008,234, an increase of 42 per cent since 2020. Raffa said it's important to put that number in context. 'A lot of people tend to panic when they hear prices are over one million,' he said. 'But the Montreal market still remains quite affordable when you compare it to those of Toronto and Vancouver.' While price in those cities stagnated and even slumped last year, Montreal home prices rose by 7 per cent. Lower mortgage rates are also having an impact, according to Rise Mortgage's Brad Weigensberg. 'The average mortgage rate for the last four months has been settling somewhere around 4.09 per cent to 4.29 per cent,' he said. 'We currently have some specials with some lenders on insured purchases at 3.69 per cent or conventional deals at 3.99, which are rates that have not really been heard of over the last six months.' Some neighbourhoods around Montreal, including Outremont, Westmount and Downtown have long surpassed the million-dollar home price mark. But suburbs are catching up, with many single-family homes approaching that price. Those high price tags are forcing first-time home buyers to get creative, according to Raffa. 'They're borrowing money or they're getting gifts from their parents. Or, you see several friends that are going in on the same home,' he said, adding that parents who own property have benefitted from the 40 per cent increase in the last five years. The good news is that there are still many homes on the market below $1 million. The mean price in Greater Montreal remains around $800,000, but it's still a seller's market and buyers will have to make some compromises, including adding a commute. While Montreal's average home price did hit the million-dollar mark once in 2024, analysts expect this trend will continue and may become the new normal as demand continues to outstrip supply.
CTV News
3 hours ago
- CTV News
Quebec liquor board prepares to destroy $300,000 worth of American alcohol
An employee removes American wines from an SAQ liquor store in Montreal on Tuesday, March 4, 2025. THE CANADIAN PRESS/Christinne Muschi MONTREAL — The Quebec liquor board may be forced to destroy $300,000 worth of American alcohol that the province has banned from stores. The provincial government on March 4 ordered the state-owned corporation to empty shelves of U.S. alcohol in response to tariffs imposed by President Donald Trump. Since then, U.S. alcohol purchased before the boycott has been kept in storage, but Quebec's liquor board says that unless the government changes its guidelines it will have to destroy some products set to expire. Affected products are mainly rosé and boxed wines, ready-to-drink cocktails, and certain beers and liqueurs not suitable for prolonged storage. 'The scenario surrounding these products has not yet been finalized and the operation is still ongoing,' liquor board spokesperson Laurianne Tardif said in a written statement. 'Several factors, including the duration of the operation, the number of products involved and future decisions regarding their fate, will have a direct impact on the potential costs.' The $300,000 worth of stock represents only a small portion of the $27 million of American products in storage. In June, liquor board president and CEO Jacques Farcy said the American products had not yet lost their value. 'These are not fresh or perishable products,' he said at the time. 'So these products retain their value. If things drag on, there may be further discussions.' He indicated it would be up to the Quebec government to decide when the liquor board could resume selling American alcohol. In March, several other provinces including Ontario and Alberta also directed their liquor regulators to stop buying American products, while B.C. banned liquor from 'red states' that voted for Trump in the 2024 election. However, Alberta and Saskatchewan have since reversed those decisions and are once again allowing the sale of U.S. alcohol. --- Stéphane Rolland, The Canadian Press With files from Maura Forrest in Montreal. This report by The Canadian Press was first published Aug. 21, 2025.
CTV News
3 hours ago
- CTV News
Back-to-school spending causing financial strain for many parents: poll
A school bag and a lunch bag are seen in the school yard as students go back to school in Montreal, on Monday, Aug. 31, 2020. THE CANADIAN PRESS/Paul Chiasson TORONTO — Back-to-school season is straining most families' budgets this year, according to a new poll, with 60 per cent of parents saying the cost of supplies has increased since last year. The online poll conducted by Leger this month found 63 per cent of parents say the return to school is having a significant impact on their finances, including nearly one-fifth who say the effect is 'very significant.' ADVERTISEMENT Compared to last year, 21 per cent of parents say the cost of supplies is 'much higher' and only a third report the cost being about the same. It's also a demanding time of year for many caregivers, with 58 per cent saying back-to-school prep is causing them stress. Eighteen per cent say it's very stressful. The polling industry's professional body, the Canadian Research Insights Council, says online surveys cannot be assigned a margin of error because they do not randomly sample the population. According to Statistics Canada's Consumer Price Index, the cost of living is up 1.7 per cent over last July, but grocery prices are rising at a higher rate — up 3.4 per cent over last year. Statistics Canada's Consumer Price Index shows the cost of stationery across Canada has risen three per cent since last year, while children's clothing has gone up by an average of 1.2 per cent across the country, with major variation between regions. It's dropped in some provinces and territories, but has risen significantly elsewhere — as much as 11.2 per cent in Saskatchewan. Cost is the most common factor influencing which supplies parents by for their kids, according to the Leger poll. Seventy-five per cent of parents say the price tag was one of their top three priorities when choosing which supplies to buy, while quality was a priority for 54 per cent and the ability to get all of their items in one place came in third, with 28 per cent listing it as an influence. While the 'Buy Canadian' movement gripped the country earlier this year, it doesn't seem to have translated to school shopping: only six per cent of parents listed the items' country of origin as a factor influencing their decision. Parents were most likely to buy the supplies from a big-box retailer such as Walmart or Canadian Tire, with 61 per cent saying that's where they go. Another 38 per cent said they bought from dollar stores. This report by The Canadian Press was first published Aug. 21, 2025. Nicole Thompson, The Canadian Press
